| Angina unstable | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000489 affected7,890 at risk
- EG001472 affected7,912 at risk
|
| Acute myocardial infarction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000359 affected7,890 at risk
- EG001303 affected7,912 at risk
|
| Angina pectoris | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000271 affected7,890 at risk
- EG001248 affected7,912 at risk
|
| Coronary artery disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000177 affected7,890 at risk
- EG001168 affected7,912 at risk
|
| Cardiac failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000178 affected7,890 at risk
- EG001155 affected7,912 at risk
|
| Cardiac failure congestive | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000135 affected7,890 at risk
- EG001125 affected7,912 at risk
|
| Atrial fibrillation | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG000135 affected7,890 at risk
- EG001123 affected7,912 at risk
|
| Coronary artery stenosis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00059 affected7,890 at risk
- EG00156 affected7,912 at risk
|
| Myocardial infarction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00054 affected7,890 at risk
- EG00156 affected7,912 at risk
|
| Myocardial ischaemia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00041 affected7,890 at risk
- EG00147 affected7,912 at risk
|
| Ventricular tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00042 affected7,890 at risk
- EG00137 affected7,912 at risk
|
| Atrial flutter | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00027 affected7,890 at risk
- EG00127 affected7,912 at risk
|
| Cardiac arrest | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00026 affected7,890 at risk
- EG00128 affected7,912 at risk
|
| Bradycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00124 affected7,912 at risk
|
| Ventricular fibrillation | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00122 affected7,912 at risk
|
| Sick sinus syndrome | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Cardiac failure chronic | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00117 affected7,912 at risk
|
| Coronary artery occlusion | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG00119 affected7,912 at risk
|
| Acute coronary syndrome | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG00117 affected7,912 at risk
|
| Cardio-respiratory arrest | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Cardiogenic shock | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG00116 affected7,912 at risk
|
| Cardiac failure acute | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Ischaemic cardiomyopathy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00014 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Supraventricular tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00114 affected7,912 at risk
|
| Left ventricular dysfunction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Arteriosclerosis coronary artery | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Mitral valve incompetence | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Left ventricular failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Aortic valve stenosis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Atrioventricular block complete | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Ventricular extrasystoles | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Arrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Atrioventricular block second degree | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Atrioventricular block | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Palpitations | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Cardiac discomfort | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Pericardial effusion | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Cardiovascular disorder | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Cardiopulmonary failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Cardiomyopathy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Atrial tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Arrhythmia supraventricular | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cardiac disorder | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cardiovascular insufficiency | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Congestive cardiomyopathy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sinus bradycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Ventricular arrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Bundle branch block left | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cardiac asthma | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Right ventricular failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acute left ventricular failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Aortic valve incompetence | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Arteriospasm coronary | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cardiac aneurysm | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cardiac tamponade | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Coronary artery insufficiency | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Myocardial fibrosis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bradyarrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diastolic dysfunction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Nodal arrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pericarditis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Postinfarction angina | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prinzmetal angina | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pulseless electrical activity | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Silent myocardial infarction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Sinus arrest | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sinus arrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Stress cardiomyopathy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Supraventricular extrasystoles | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tricuspid valve disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Aortic valve disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Aortic valve disease mixed | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Atrial thrombosis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Atrioventricular block first degree | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Atrioventricular dissociation | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bifascicular block | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bundle branch block right | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiac valve disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiovascular deconditioning | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Chronic left ventricular failure | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Chronotropic incompetence | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Conduction disorder | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cor pulmonale chronic | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Extrasystoles | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypertensive cardiomyopathy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypertensive heart disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Intracardiac thrombus | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Left ventricular hypertrophy | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mitral valve disease | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mitral valve stenosis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Myocarditis | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pericardial haemorrhage | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pericarditis constrictive | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sinoatrial block | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Sinus tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Supraventricular tachyarrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Systolic dysfunction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Torsade de pointes | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Trifascicular block | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ventricular dyssynchrony | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ventricular tachyarrhythmia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG000160 affected7,890 at risk
- EG001139 affected7,912 at risk
|
| Cellulitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00046 affected7,890 at risk
- EG00138 affected7,912 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00036 affected7,890 at risk
- EG00143 affected7,912 at risk
|
| Gastroenteritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00029 affected7,890 at risk
- EG00131 affected7,912 at risk
|
| Sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00023 affected7,890 at risk
- EG00135 affected7,912 at risk
|
| Bronchitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00124 affected7,912 at risk
|
| Appendicitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Septic shock | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00025 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Urosepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00114 affected7,912 at risk
|
| Diverticulitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Lobar pneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Erysipelas | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00014 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Bronchopneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Localised infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Lower respiratory tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Pyelonephritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Osteomyelitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Respiratory tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Device related infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Influenza | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Lung infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Staphylococcal infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Gastroenteritis viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Herpes zoster | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Peritonitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Wound infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Postoperative wound infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Gangrene | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Post procedural infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Appendicitis perforated | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Infective exacerbation of chronic obstructive airways disease | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Viral infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arthritis infective | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Cholecystitis infective | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Clostridium difficile infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pulmonary tuberculosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pyelonephritis acute | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Anal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Arthritis bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Clostridium difficile colitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cystitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diabetic gangrene | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Endocarditis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Enterocolitis infectious | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Escherichia bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Escherichia sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Orchitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pneumonia bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Postoperative abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Skin infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Abdominal wall abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Abscess limb | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dengue fever | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diabetic foot infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Enterococcal sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| H1N1 influenza | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Haematoma infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intervertebral discitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pneumonia klebsiella | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Salmonellosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Sepsis syndrome | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Soft tissue infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Staphylococcal bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Streptococcal bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Acute hepatitis B | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Arteriosclerotic gangrene | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bacterial pyelonephritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Campylobacter gastroenteritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chronic sinusitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Device related sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dysentery | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ear infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Escherichia urinary tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Extradural abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastritis viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastroenteritis salmonella | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Giardiasis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatitis B | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Implant site infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Infected skin ulcer | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Infectious pleural effusion | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Klebsiella bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Klebsiella sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Liver abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lyme disease | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nasopharyngitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Osteomyelitis chronic | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Peritonsillar abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pharyngitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pneumonia streptococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pseudomonal bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pyelonephritis chronic | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retroperitoneal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Scrotal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Streptococcal infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Streptococcal sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Subcutaneous abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urinary tract infection bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Abdominal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Abdominal infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Abdominal sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Abdominal wall infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Abscess jaw | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Acute pulmonary histoplasmosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Amoebiasis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Appendiceal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bacterial sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Biliary sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bone abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Borrelia infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bronchitis bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bursitis infective | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Carbuncle | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Catheter site infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cellulitis gangrenous | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cellulitis staphylococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cholangitis suppurative | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diarrhoea infectious | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Disseminated tuberculosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Echinococciasis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Empyema | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Endocarditis bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Endocarditis enterococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Endocarditis staphylococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Endometritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Endophthalmitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Enteritis infectious | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Enterobacter infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Enterococcal bacteraemia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Enterococcal infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Epiglottitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Escherichia infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| External ear cellulitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Febrile infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Fungal oesophagitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gallbladder empyema | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastroenteritis rotavirus | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastrointestinal viral infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Genital infection fungal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Graft infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Groin abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| HIV infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Helicobacter gastritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Helicobacter infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatitis A | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatitis C | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatitis E | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatitis viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Herpes zoster ophthalmic | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Histoplasmosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Infected bites | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Infective myositis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intertrigo candida | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Keratitis herpetic | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Kidney infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Laryngitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Leptospirosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lung abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lymphangitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mastoiditis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mediastinitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Meningitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Meningitis bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Meningitis cryptococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mycoplasma infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mycotoxicosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Necrotising fasciitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oesophageal candidiasis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oral candidiasis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Otitis media | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Otitis media chronic | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Paronychia | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Parotitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Perineal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Periorbital cellulitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Peritoneal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Peritonsillitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Plasmodium vivax infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pneumococcal sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pneumonia chlamydial | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pneumonia necrotising | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pneumonia viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostatic abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pseudomembranous colitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pseudomonas infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Psoas abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pulmonary sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pyopneumothorax | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Respiratory tract infection viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retroperitoneal infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Salmonella sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Scrub typhus | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Septic embolus | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sialoadenitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Sinobronchitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Sinusitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Staphylococcal osteomyelitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Staphylococcal sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Subacute endocarditis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Superinfection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Suspected transmission of an infectious agent via product | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tinea pedis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tongue abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tonsillitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tooth abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tracheitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tracheobronchitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tracheobronchitis viral | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tuberculosis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urethritis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Urinary tract infection pseudomonal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vaginal abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Varicella | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vestibular neuronitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Viral tracheitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Viral upper respiratory tract infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Wound infection staphylococcal | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Wound sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ischaemic stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00097 affected7,890 at risk
- EG00194 affected7,912 at risk
|
| Transient ischaemic attack | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00087 affected7,890 at risk
- EG00167 affected7,912 at risk
|
| Syncope | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00079 affected7,890 at risk
- EG00172 affected7,912 at risk
|
| Carotid artery stenosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00047 affected7,890 at risk
- EG00148 affected7,912 at risk
|
| Cerebrovascular accident | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00028 affected7,890 at risk
- EG00133 affected7,912 at risk
|
| Dizziness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00118 affected7,912 at risk
|
| Haemorrhagic stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Ischaemic cerebral infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00020 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Presyncope | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00116 affected7,912 at risk
|
| Cerebral infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Convulsion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Epilepsy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Headache | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Sciatica | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Subarachnoid haemorrhage | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Brain stem infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Embolic stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Loss of consciousness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Carotid artery occlusion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cervicobrachial syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Dementia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Diabetic neuropathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Lacunar infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cerebral haemorrhage | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Carpal tunnel syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Haemorrhage intracranial | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Vertebrobasilar insufficiency | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Aphasia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Carotid artery disease | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Embolic cerebral infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hemiparesis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tremor | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Ataxia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Carotid arteriosclerosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metabolic encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Neuralgia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| VIIth nerve paralysis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Altered state of consciousness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Cerebral ischaemia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cognitive disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Dysarthria | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoglycaemic coma | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intercostal neuralgia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Paraesthesia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Polyneuropathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Thalamic infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Vascular dementia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Amyotrophic lateral sclerosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Balance disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Brain oedema | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain stem haemorrhage | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebellar haemorrhage | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebral arteriosclerosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebral haematoma | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebrovascular disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cervical myelopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Coma | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dementia Alzheimer's type | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Depressed level of consciousness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Grand mal convulsion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hydrocephalus | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoaesthesia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoxic-ischaemic encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Intracranial aneurysm | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Migraine | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mononeuritis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Nerve compression | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nervous system disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Normal pressure hydrocephalus | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Paraplegia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Post herpetic neuralgia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pseudoradicular syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Radiculopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Reversible ischaemic neurological deficit | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Senile dementia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Somnolence | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spondylitic myelopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Thrombotic cerebral infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Transient global amnesia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vertebral artery stenosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Alcoholic seizure | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Basal ganglia infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Brain injury | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain midline shift | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain stem ischaemia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Brain stem stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cauda equina syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Central nervous system lesion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cerebellar infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebral artery embolism | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cerebral artery occlusion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cerebral artery stenosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cerebral circulatory failure | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Complex partial seizures | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Complex regional pain syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Critical illness polyneuropathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dementia with Lewy bodies | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diabetic hyperosmolar coma | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diabetic mononeuropathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Disturbance in attention | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dizziness exertional | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dizziness postural | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dysaesthesia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dyslalia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dystonia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Encephalitis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Encephalomalacia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Facial paresis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Guillain-Barre syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Haemorrhagic cerebral infarction | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Haemorrhagic transformation stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hemianopia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hemiplegic migraine | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypertensive encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoglycaemic unconsciousness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypotonia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Intraventricular haemorrhage | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ischaemic neuropathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lethargy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Memory impairment | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Meningoradiculitis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Monoparesis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Movement disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Nerve root compression | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Neuritis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Neuritis cranial | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Neurological symptom | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neuropathy peripheral | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Orthostatic intolerance | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Paresis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Parkinson's disease | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Partial seizures with secondary generalisation | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Peripheral nerve paresis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Polyneuropathy chronic | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Radicular syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Radiculitis lumbosacral | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Restless legs syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retrograde amnesia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ruptured cerebral aneurysm | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sensory disturbance | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Sensory loss | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Simple partial seizures | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spinal claudication | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Spinal cord compression | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spinal cord disorder | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spinal haematoma | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Status epilepticus | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Stupor | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Thrombotic stroke | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Trigeminal neuralgia | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| VIth nerve paralysis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vascular encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vascular parkinsonism | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vertigo CNS origin | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vocal cord paralysis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| White matter lesion | Nervous system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Non-cardiac chest pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG000196 affected7,890 at risk
- EG001191 affected7,912 at risk
|
| Death | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00073 affected7,890 at risk
- EG00156 affected7,912 at risk
|
| Sudden death | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00056 affected7,890 at risk
- EG00157 affected7,912 at risk
|
| Sudden cardiac death | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00022 affected7,890 at risk
- EG00124 affected7,912 at risk
|
| Chest pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Asthenia | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Pyrexia | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Device occlusion | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Fatigue | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Chest discomfort | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Oedema peripheral | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Multi-organ failure | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Device malfunction | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Hernia | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Malaise | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Medical device complication | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Device dislocation | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Adverse drug reaction | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gait disturbance | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Thrombosis in device | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| General physical health deterioration | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ill-defined disorder | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Medical device pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Spinal pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ulcer haemorrhage | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Axillary pain | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiac complication associated with device | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chills | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Device battery issue | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Device lead damage | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Device lead issue | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Device power source issue | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Drowning | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Drug intolerance | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Exercise tolerance decreased | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Face oedema | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Fat necrosis | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Generalised oedema | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypothermia | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Impaired healing | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Implant site thrombosis | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Inflammation | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Influenza like illness | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ischaemic ulcer | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lipogranuloma | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Medical device site reaction | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Multi-organ disorder | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nodule | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Polyp | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Puncture site haemorrhage | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Stent embolisation | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Systemic inflammatory response syndrome | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vestibulitis | General disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Inguinal hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00048 affected7,890 at risk
- EG00131 affected7,912 at risk
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00026 affected7,890 at risk
- EG00130 affected7,912 at risk
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00021 affected7,890 at risk
- EG00123 affected7,912 at risk
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00025 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Large intestine polyp | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00121 affected7,912 at risk
|
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00118 affected7,912 at risk
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00114 affected7,912 at risk
|
| Gastritis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Pancreatitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Gastric ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00117 affected7,912 at risk
|
| Nausea | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Colitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Pancreatitis acute | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Vomiting | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Ileus | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Umbilical hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Diverticulum intestinal | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Duodenal ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Abdominal hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Colitis ischaemic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Duodenal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Gastric ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Gastric haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Gastritis erosive | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Intestinal ischaemia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Ascites | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Dysphagia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Melaena | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Diverticulum | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Oesophagitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Pancreatitis chronic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diverticulum intestinal haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Duodenitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Gastritis haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Anal fistula | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Enterovesical fistula | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Haematemesis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Mallory-Weiss syndrome | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oesophageal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Peptic ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Colitis ulcerative | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diverticulitis intestinal haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Gastric polyps | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Haematochezia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hiatus hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Inguinal hernia, obstructive | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intestinal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Intestinal perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Large intestine perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Peptic ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Umbilical hernia, obstructive | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Abdominal distension | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Abdominal strangulated hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Abdominal wall haematoma | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Crohn's disease | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diaphragmatic hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diverticular perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Duodenal ulcer perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Enteritis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Enterocolitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Erosive duodenitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Faecal incontinence | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastritis atrophic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastrointestinal necrosis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastrointestinal angidysplasia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haemorrhoidal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Ileus paralytic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Large intestinal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Oesophageal varices haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Proctitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Rectal polyp | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Rectal prolapse | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Stomach mass | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Volvulus | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Abdominal adhesions | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Abdominal hernia obstructive | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Abdominal wall mass | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Acute abdomen | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Alcoholic pancreatitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Anal fissure | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Anorectal disorder | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Appendix disorder | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Buccal polyp | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Colonic stenosis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dental caries | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diabetic gastroparesis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diarrhoea haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dieulafoy's vascular malformation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Duodenal polyp | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Duodenal vascular ectasia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Epigastric discomfort | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Erosive oesophagitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Faeces discoloured | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Femoral hernia, obstructive | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Frequent bowel movements | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gallstone ileus | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastric dysplasia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastroduodenal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastroduodenitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal erosion | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal ischaemia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal motility disorder | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal angiodysplasia haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrooesophagitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haemorrhagic erosive gastritis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypoaesthesia oral | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ileal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ileitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Internal hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Intestinal infarction | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intestinal polyp | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Large intestinal ulcer | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lip haematoma | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lumbar hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mesenteric artery stenosis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mesenteric occlusion | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mesenteric panniculitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mouth cyst | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Oedema mouth | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Oedematous pancreatitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Oesophageal dysplasia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Oesophageal perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oesophageal ulcer haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oesophageal varices haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oral pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pancreatic calcification | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pancreatic disorder | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pancreatitis haemorrhagic | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pancreatitis necrotising | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Papilla of | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Paraesthesia oral | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Peptic ulcer perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pneumatosis intestinalis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Poor dental condition | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Proctalgia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Proctitis ulcerative | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Reflux gastritis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retroperitoneal haematoma | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retroperitoneal haemorrhage | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Small intestinal perforation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spigelian hernia | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Subileus | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tooth disorder | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Toothache | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00064 affected7,890 at risk
- EG00167 affected7,912 at risk
|
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00037 affected7,890 at risk
- EG00133 affected7,912 at risk
|
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00032 affected7,890 at risk
- EG00121 affected7,912 at risk
|
| Bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00121 affected7,912 at risk
|
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00117 affected7,912 at risk
|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Adenocarcinoma of colon | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Metastases to liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Renal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Hepatic cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Basal Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Metastases to bone | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Metastases to lymph node | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Metastases to lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Small Cell Lung Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Colon adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Laryngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Lung adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Non-Small cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Oesophageal Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Renal Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Chronic lymphocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Prostate cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Bladder neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Cholangiocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Plasma cell myeloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Prostatic adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Myelodysplastic syndrome | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Rectal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Adenocarcinoma gastric | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Adenocarcinoma pancreas | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Bladder transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatic cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Meningioma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metastatic lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Benign neoplasm of bladder | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Benign salivary gland neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bile duct cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bladder cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metastases to spine | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastatic malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Metastatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Adenoma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chronic myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Endometrial cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Lipoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Malignant neoplasm of unknown primary site | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Metastases to adrenals | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Non-Hodgkin's lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Non-small cell lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Oesophageal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Penile cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Squamous cell carcinoma of lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Benign breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Benign neoplasm of thyroid gland | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bile duct adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bone cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain neoplasm benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cancer pain | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Carcinoid tumour of the duodenum | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cervix carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Colorectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Endometrial adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Gallbladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastric adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Glioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypopharyngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Laryngeal squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lymphocytic lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Malignant peritoneal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metastases to abdominal cavity | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Metastatic carcinoma of the bladder | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neoplasm prostate | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pancreatic carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Renal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Throat cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Tonsil cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ureteric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acoustic neuroma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acute lymphocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Adenoid cystic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Adrenocortical carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ameloblastoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Anaplastic astrocytoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Angiosarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Benign anorectal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Benign hepatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Benign lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Benign ovarian tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bladder papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bowen's disease | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Brain neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Breast cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Breast cancer stage I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Carcinoid tumour of the gastrointestinal tract | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiac myxoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Chondrosarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Chronic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chronic lymphocytic leukaemia stage 0 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Clear cell renal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Colon cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Colon cancer stage 0 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Colon cancer stage II | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Colorectal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diffuse large B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Endometrial cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastric cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal stromal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal tract adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Glioblastoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Glottis carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haemangioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypopharyngeal cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intraductal papillary-mucinous carcinoma of pancreas | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Invasive lobular breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Large intestine benign neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Laryngeal cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Leiomyosarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lentigo maligna | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lip and/or oral cavity cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lip neoplasm malignant stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lung adenocarcinoma stage II | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lung adenocarcinoma stage IV | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lung adenocarcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lung carcinoma cell type unspecified recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lung carcinoma cell type unspecified stage III | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lung squamous cell carcinoma stage III | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lymphangiosis carcinomatosa | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Malignant melanoma in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Malignant neoplasm of ampulla of Vater | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Malignant palate neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mantle cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mediastinum neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mesothelioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Metastases to biliary tract | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastases to peritoneum | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Metastases to pleura | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastases to the mediastinum | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastatic bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastatic salivary gland cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metastatic squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Morton's neuroma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neurilemmoma benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Neuroendocrine carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Optic nerve neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Parathyroid tumour benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Peritoneal carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Phaeochromocytoma malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pituitary tumour benign | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pleural mesothelioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Polycythaemia vera | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostate cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Rectosigmoid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Salivary gland adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Salivary gland neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Sarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Signet-ring cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Skin cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Small cell lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Small intestine adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Soft tissue cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Squamous cell carcinoma of the oral cavity | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Squamous cell carcinoma of the tongue | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Testicular malignant teratoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Thymoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Thyroid adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Transitional cell cancer of the renal pelvis and ureter | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tumour haemorrhage | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tumour invasion | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ureteral neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Urinary bladder adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urinary tract neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Uterine cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Peripheral arterial occlusive disease | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00055 affected7,890 at risk
- EG00146 affected7,912 at risk
|
| Hypotension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00039 affected7,890 at risk
- EG00127 affected7,912 at risk
|
| Hypertension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00032 affected7,890 at risk
- EG00129 affected7,912 at risk
|
| Aortic aneurysm | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00135 affected7,912 at risk
|
| Peripheral vascular disorder | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00027 affected7,890 at risk
- EG00124 affected7,912 at risk
|
| Intermittent claudication | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00028 affected7,890 at risk
- EG00121 affected7,912 at risk
|
| Peripheral artery stenosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00021 affected7,890 at risk
- EG00123 affected7,912 at risk
|
| Peripheral ischaemia | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00020 affected7,890 at risk
- EG00119 affected7,912 at risk
|
| Aortic stenosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00116 affected7,912 at risk
|
| Hypertensive crisis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Haematoma | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00013 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Femoral artery occlusion | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Circulatory collapse | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Orthostatic hypotension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Arteriosclerosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Hypovolaemic shock | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Peripheral artery aneurysm | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Peripheral artery thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Varicose vein | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Iliac artery occlusion | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arterial stenosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Aortic dissection | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Extremity necrosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Haemorrhage | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Subclavian artery stenosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Venous thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Aortic aneurysm rupture | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Arterial occlusive disease | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Diabetic vascular disorder | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Thrombophlebitis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Ischaemia | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Peripheral embolism | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Shock | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Shock haemorrhagic | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Venous insufficiency | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Accelerated hypertension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Aortic thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Arterial disorder | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Arteriovenous fistula | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Embolism | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypertensive emergency | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Phlebitis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Subclavian artery occlusion | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Venous stenosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Venous thrombosis limb | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Aneurysm | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Aneurysm ruptured | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Angiopathy | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Aortic arteriosclerosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Aortic calcification | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Aortic dilatation | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arterial insufficiency | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arterial rupture | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Artery dissection | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bleeding varicose vein | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Blood pressure fluctuation | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Embolism venous | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Extravasation blood | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Femoral artery aneurysm | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haematocoele | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoperfusion | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Iliac artery rupture | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Infarction | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intra-abdominal haematoma | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ischaemic limb pain | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lymphocele | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Orthostatic hypertension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pelvic venous thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Phlebitis superficial | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Poor peripheral circulation | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Raynaud's phenomenon | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renovascular hypertension | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Subclavian artery aneurysm | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Subclavian steal syndrome | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Temporal arteritis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Thromboangiitis obliterans | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Varicose ulceration | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Varicose vein ruptured | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vascular insufficiency | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Coronary artery restenosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00028 affected7,890 at risk
- EG00119 affected7,912 at risk
|
| Fall | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Femur fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Hip fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Subdural haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00115 affected7,912 at risk
|
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Head injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Tendon rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Laceration | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Radius fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Post procedural complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Post procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Toxicity to various agents | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Meniscus injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Vascular graft occlusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Multiple injuries | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Vascular graft complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Vascular pseudoaneurysm | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Arterial restenosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Joint injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Lower limb fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Pelvic fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Concussion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Fibula fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Incisional hernia | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Lumbar vertebral fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Overdose | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Patella fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Wound | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Alcohol poisoning | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Craniocerebral injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Graft thrombosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Limb injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Post procedural myocardial infarction | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Subdural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Foot fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Limb traumatic amputation | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Thermal burn | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Acetabulum fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arterial injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Burns second degree | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Excoriation | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gun shot wound | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Incisional hernia, Obstruction | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ligament rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Multiple fractures | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Postoperative respiratory failure | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Brain contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Comminuted fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ligament injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Liver contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Muscle strain | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Postoperative hernia | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Procedural complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Procedural hypotension | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pubis fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Skull fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Suture related complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Transplant failure | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Traumatic renal injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vascular bypass dysfunction | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Wound necrosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Accident at home | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Anaemia postoperative | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Animal bite | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Arteriovenous fistula thrombosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Back injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Burns first degree | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiac function disturbance postoperative | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cardiac procedure complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Carotid artery restenosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Chest injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Eschar | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Extradural haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Eye injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Eye penetration | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Face injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Forearm fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Foreign body | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Fractured sacrum | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gastrointestinal disorder postoperative | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gastrointestinal stoma complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hand fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Heart injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Incision site haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Inflammation of wound | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Internal injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intervertebral disc injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Jaw fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Kidney contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Limb crushing injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mental status changes postoperative | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Muscle rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Periprosthetic fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Perirenal haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Poisoning | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Post laminectomy syndrome | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Post procedural fistula | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Post procedural haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Post procedural stroke | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Post procedural swelling | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Postoperative ileus | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Postoperative thoracic procedure complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Postoperative thrombosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Procedural headache | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Procedural nausea | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Procedural vomiting | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pulmonary contusion | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Shunt stenosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Skull fractured base | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Soft tissue injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spinal column injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Spinal fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Splenic rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Splinter | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Subcutaneous haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Synovial rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tendon injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Testicular injury | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Transfusion reaction | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Traumatic haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Traumatic intracranial haemorrhage | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ulna fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urinary bladder rupture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vascular graft thrombosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vascular procedure complication | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Venomous sting | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Wound evisceration | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Wound haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00052 affected7,890 at risk
- EG00150 affected7,912 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00039 affected7,890 at risk
- EG00152 affected7,912 at risk
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00026 affected7,890 at risk
- EG00135 affected7,912 at risk
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00118 affected7,912 at risk
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00020 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00117 affected7,912 at risk
|
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00018 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG00014 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Bronchitis chronic | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Lung disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Bronchiectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Lung infiltration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pulmonary mass | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Haemothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Obstructive airways disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pulmonary congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bronchial hyperreactivity | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Bronchopulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hydropneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Idiopathic pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Nasal septum deviation | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Respiratory arrest | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acute lung injury | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acute respiratory distress syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Apnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Asphyxia | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bronchopleural fistula | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diaphragmatic disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diaphragmatic paralysis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Emphysema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hydrothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Increased upper airway secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Laryngeal cyst | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Laryngeal oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Laryngospasm | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lung consolidation | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Lung cyst | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mediastinal haematoma | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mediastinal haemorrhage | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nasal mucosal hypertrophy | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nasal polyps | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Nasal turbinate hypertrophy | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Organising pneumonia | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Orthopnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Painful respiration | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pharyngeal oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pulmonary arterial hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pulmonary haemorrhage | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Restrictive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Snoring | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Status asthmaticus | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vocal cord thickening | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00078 affected7,890 at risk
- EG00173 affected7,912 at risk
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00027 affected7,890 at risk
- EG00120 affected7,912 at risk
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00116 affected7,912 at risk
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Spinal column stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG00113 affected7,912 at risk
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Rotator cuff syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Cervical spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Spondylolisthesis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Polymyalgia rheumatica | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Gouty arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Osteonecrosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Intervertebral disc degeneration | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Periarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Arthritis reactive | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Muscle haemorrhage | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Articular calcification | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Foot deformity | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Intervertebral disc displacement | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Osteitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Polyarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Scoliosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spondylitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tendon disorder | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Arthropathy | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Back disorder | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone erosion | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone fistula | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone lesion | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chondromalacia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Chondropathy | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Costochondritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dupuytren's contracture | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Exostosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Fistula | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haemarthrosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Inclusion body myositis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Inguinal mass | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Joint effusion | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Joint swelling | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Limb discomfort | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Metatarsalgia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Monarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Musculoskeletal discomfort | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Myofascial pain syndrome | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Myositis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Osteochondrosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Osteoporosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Osteoporotic fracture | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pathological fracture | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spinal deformity | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Spondylolysis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Synovitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Tendonitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tenosynovitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tenosynovitis stenosans | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vertebral foraminal stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal failure acute | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00061 affected7,890 at risk
- EG00183 affected7,912 at risk
|
| Renal failure | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG00131 affected7,912 at risk
|
| Haematuria | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00015 affected7,890 at risk
- EG00112 affected7,912 at risk
|
| Urinary retention | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00019 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Renal failure chronic | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00013 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00010 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Renal impairment | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Calculus ureteric | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Renal colic | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Urethral stenosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Renal artery stenosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Hydronephrosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Acute prerenal failure | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Calculus urinary | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Renal cyst | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Renal tubular necrosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Calculus bladder | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diabetic nephropathy | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Nephrotic syndrome | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Cystitis noninfective | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Micturition disorder | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal infarct | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tubulointerstitial nephritis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Ureteric obstruction | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ureteric stenosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urinary bladder polyp | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urinary incontinence | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Urinary tract obstruction | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bladder dilatation | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bladder discomfort | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bladder dysfunction | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bladder hypertrophy | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cystitis glandularis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cystitis haemorrhagic | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cystitis ulcerative | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dysuria | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Glomerulonephritis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Glomerulonephritis Chronic | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Incontinence | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lower urinary tract symptoms | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nephritic syndrome | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neurogenic bladder | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pollakiuria | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal artery dissection | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Renal artery arteriosclerosis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal cyst haemorrhage | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Renal haemorrhage | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Renal mass | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Renal painr | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Stress urinary incontinence | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Urethral disorder | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Urinary bladder haemorrhage | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG00037 affected7,890 at risk
- EG00127 affected7,912 at risk
|
| Dehydration | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00133 affected7,912 at risk
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG00026 affected7,890 at risk
- EG00124 affected7,912 at risk
|
| Diabetes mellitus inadequate control | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00126 affected7,912 at risk
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0009 affected7,890 at risk
- EG00111 affected7,912 at risk
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG00110 affected7,912 at risk
|
| Gout | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diabetic ketoacidosis | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Hypovolaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Obesity | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Electrolyte imbalance | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Fluid overload | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Malnutrition | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Metabolic acidosis | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Type 1 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cachexia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Failure to thrive | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypertriglyceridaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ketoacidosis | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Acidosis | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diabetic complication | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Fluid retention | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Fructose intolerance | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypercalcaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperlipidaemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperosmolar state | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hypophosphataemia | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Insulin-requiring type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Metabolic syndrome | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vitamin B12 deficiency | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Vitamin D deficiency | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00028 affected7,890 at risk
- EG00130 affected7,912 at risk
|
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG00024 affected7,890 at risk
- EG00119 affected7,912 at risk
|
| Cholecystitis chronic | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Bile duct stone | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Cholangitis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Jaundice cholestatic | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Biliary colic | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Hepatic steatosis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatic cirrhosis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Hepatic failure | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Acute hepatic failure | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cholangitis acute | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cholelithiasis obstructive | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cholestasish | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gallbladder disorder | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatitis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hepatitis alcoholic | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatocellular injury | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatotoxicity | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ischaemic hepatitis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Jaundice | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Portal hypertension | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Alcoholic liver disease | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bile duct obstruction | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bile duct stenosis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Biliary fistula | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Drug-induced liver injury | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gallbladder pain | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gallbladder perforation | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatic cyst | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatic haemorrhage | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatic mass | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatitis acute | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hepatitis toxic | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatorenal failure | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hydrocholecystis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Liver injury | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Pneumobilia | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG00052 affected7,890 at risk
- EG00142 affected7,912 at risk
|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Disseminated intravascular coagulation | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Haemorrhagic anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Coagulopathy | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypochromic anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Microcytic anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Anaemia macrocytic | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Anaemia megaloblastic | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Anaemia of chronic disease | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bone marrow failure | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bone marrow ischaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Haemolytic anaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperprothrombinaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Idiopathic thrombocytopenic purpura | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Jaundice acholuric | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pancytopenia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Polycythaemia | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Spontaneous haematoma | Blood and lymphatic system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG00028 affected7,890 at risk
- EG00131 affected7,912 at risk
|
| Prostatitis | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0019 affected7,912 at risk
|
| Prostatomegaly | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Ovarian cyst | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Uterine polyp | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Acquired phimosis | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Uterine prolapse | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Epididymitis | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Endometrial hyperplasia | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Epididymal cyst | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Scrotal oedema | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Acquired hydrocele | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Breast enlargement | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cervical dysplasia | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Genital pain | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Gynaecomastia | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ovarian mass | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pelvic fluid collection | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Penile swelling | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Peyronie's disease | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostatic disorder | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Prostatic obstruction | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostatism | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Scrotal swelling | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Uterovaginal prolapse | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vaginal polyp | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vaginal prolapse | Reproductive system and breast disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Alanine aminotransferase increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG00011 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Hepatic enzyme increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| International normalised ratio increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Weight decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Aspartate aminotransferase increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Liver function test abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Blood bilirubin increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Troponin increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Blood creatinine increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Blood glucose increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Haemoglobin decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Blood pressure increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Ejection fraction decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Electrocardiogram ST segment depression | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Prostatic specific antigen increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Blood potassium decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Blood pressure decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Cardiac stress test abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Heart rate decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Heart rate irregular | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Intraocular pressure increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Troponin I increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Activated partial thromboplastin time prolonged | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Alanine aminotransferase abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Aspartate aminotransferase abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Bile output abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Bilirubin conjugated increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Blood alkaline phosphatase increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Blood glucose decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Blood urea increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Blood urine present | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| C-reactive protein increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cardiac murmur | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Carotid bruit | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| ECG signs of myocardial ischaemia | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Heart rate increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hepatic enzyme abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Occult blood positive | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Oxygen saturation decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Red blood cell sedimentation rate increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Scan myocardial perfusion abnormal | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Streptococcus test positive | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Stroke volume decreased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Transaminases increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| White blood cell count increased | Investigations | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Confusional state | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG00012 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Depression | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0007 affected7,890 at risk
- EG0018 affected7,912 at risk
|
| Delirium | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0017 affected7,912 at risk
|
| Mental status changes | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Anxiety | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Suicide attempt | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Alcohol withdrawal syndrome | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Completed suicide | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Alcohol abuse | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Anxiety disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Insomnia | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Major depression | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Suicidal ideation | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Conversion disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hallucination | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Psychotic disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Suicidal behaviour | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Aggression | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Agitation | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Alcoholism | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Depression suicidal | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Disorientation | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dysthymic disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Emotional distress | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hallucination, auditory | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Impulse-control disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Mania | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Mental disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Panic attack | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Psychogenic seizure | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Sleep disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Somatoform disorder cardiovascular | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Cataract | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG00016 affected7,890 at risk
- EG00116 affected7,912 at risk
|
| Retinal detachment | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Amaurosis fugax | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vitreous haemorrhage | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Diabetic retinopathy | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Diplopia | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Glaucoma | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Blindness | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ocular vascular disorder | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retinal artery occlusion | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Retinal ischaemia | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Retinal tear | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retinal vein occlusion | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vision blurred | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Blindness unilateral | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Conjunctivitis | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Dacryostenosis acquired | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Diabetic eye disease | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eye disorder | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eye haemorrhage | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eye pain | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eyelid ptosis | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ocular retrobulbar haemorrhag | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Diabetic foot | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG00014 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Ophthalmoplegia | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Optic ischaemic neuropathy | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pterygium | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retinal artery thrombosis | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retinal degeneration | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retinal haemorrhage | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Retinal vascular thrombosis | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Retinopathy | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ulcerative keratitis | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Visual acuity reduced | Eye disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0008 affected7,890 at risk
- EG0015 affected7,912 at risk
|
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Actinic keratosis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Blister | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Cold sweat | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Drug eruption | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Ecchymosis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Eczema asteatotic | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Erythema multiforme | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Erythema nodosum | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Keloid scar | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Leukocytoclastic vasculitis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Neuropathic ulcer | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Pemphigoid | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Pyoderma gangrenosum | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Rash generalised | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Skin disorder | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Skin necrosis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Stasis dermatitis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Swelling face | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vertigo | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0006 affected7,890 at risk
- EG00114 affected7,912 at risk
|
| Vestibular disorder | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Vertigo positional | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Vertigo labyrinthine | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Deafness | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Sudden hearing loss | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Otosclerosis | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Ototoxicity | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Tinnitus | Ear and labyrinth disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperthyroidism | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0004 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Goitre | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0013 affected7,912 at risk
|
| Adrenal disorder | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Adrenal insufficiency | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperparathyroidism | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hyperparathyroidism primary | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypothyroidism | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Thyroid cyst | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Thyroid disorder | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Toxic nodular goitre | Endocrine disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Hydrocele | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0005 affected7,890 at risk
- EG0016 affected7,912 at risk
|
| Atrial septal defect | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Hypertrophic cardiomyopathy | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Arteriovenous malformation | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Congenital coronary artery malformation | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Spinal vessel congenital anomaly | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Syringomyelia | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Anaphylactic reaction | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0014 affected7,912 at risk
|
| Allergy to arthropod sting | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0003 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Hypersensitivity | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0002 affected7,890 at risk
- EG0012 affected7,912 at risk
|
| Allergy to arthropod bite | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Allergic oedema | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Food allergy | Immune system disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Disability | Social circumstances | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Coronary revascularisation | Surgical and medical procedures | MedDRA 16.0 | Systematic Assessment | | - EG0001 affected7,890 at risk
- EG0010 affected7,912 at risk
|
| Nasal cyst | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment | | - EG0000 affected7,890 at risk
- EG0011 affected7,912 at risk
|
| Deep vein thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment | | - EG00017 affected7,890 at risk
- EG00110 affected7,912 at risk
|